Loading…
← CockpitCompetitor Analysis › IART Integra LifeSciences Holdings CorporationOpen in the cockpit ↗

Integra LifeSciences Holdings CorporationIARTCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of regenerative tissue products, neurosurgery devices and surgical instruments used in wound care and brain surgery.

Momentum neutral 40
Mkt cap
$1.08B
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$15.6M
20-day average traded
Fwd P/E
6.0×
forward earnings
ROIC−WACC
-2.1 pp
WACC 7.6%
Hurdle
+2 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · USD$13.86
1D+2.3%
1W-6.2%
1M+4.0%
3M-16.5%
6M-9.9%
YTD+11.6%
1Y+18.2%
ATR %5.5%
Beta1.59
52w lowhigh32.4% off high

What Integra LifeSciences does

Maker of regenerative tissue products, neurosurgery devices and surgical instruments used in wound care and brain surgery.

Sold to hospitals through a direct sales force and bought on surgeon preference and hospital contracts, with procedure volumes in neurosurgery and wound care driving reorders. Much of the portfolio was built through acquisitions of smaller device companies over many years.

Products and services

  • Skin/wound regenerative matrices (Integra, PriMatrix)
  • Neurosurgery devices (CUSA, shunts, ICP monitors)
  • Legacy Codman-brand surgical instruments
  • Tissue reconstruction products

Customers

  • Wound care/plastic surgeons
  • Neurosurgeons
  • Hospitals

Where it sits in the supply chain

  • Medical devices
  • Regenerative medicine & neurosurgery
  • Wound care, neurosurgery and surgical…

What could go right

  • Wound care/chronic wound treatment growth
  • Neurosurgery procedure volume growth

What could go wrong

  • Manufacturing quality/regulatory compliance issues (past FDA warnings)
  • Reimbursement pressure

Moat: narrow (regulatory licence, brand, installed base). Regulatory-approved regenerative-tissue brands with established surgeon relationships across two specialties.

Headquarters: Princeton, New Jersey · Founded: 1989 · Employees: 4,427

Named competitors

Integra LifeSciences at a glance

Size Integra LifeSciences (IART) is a United States Health Care company (Medical Specialties) with a market value of $1.08B, the 2182nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.86 on 18 Nov 2026.

Performance Over six months the shares fell 9.9%, against -4.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 0.8% over the last twelve months (peer median +10.4%); the operating margin is 11.6% (peer median 11.8%).

Valuation It trades at 6.0× forward earnings against a peer median of 18.5× (cheapest of 12).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.1 points below its cost of capital (7.6% WACC).

Short interest Short interest is 10.2% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 95IART 92
Six months, rebased to 100: Integra LifeSciences against the median of its 20 peers (local-currency closes).

Integra LifeSciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.66B$1.64B$1.61B$1.54B$1.56B
Revenue growth—+2%+4%-1%—
Gross profit$909M$862M$899M$894M$928M
EBITDA$347M$334M$323M$344M$391M
Net income$13.0M-$516M-$6.94M$67.7M$181M
Free cash flow$85.8M-$31.1M$25.0M$73.1M$222M
Capital expenditure$68.8M$95.6M$114M$66.9M$47.1M
Total debt$2.00B$2.03B$1.98B$1.68B$1.62B

Quarterly statements and history in the cockpit →

Integra LifeSciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%214150301101688622SIBNATECIRMDDRTS300406CSTLEUZ6000553010216523688161300685300206CBLL300143TNDMIART6-month return →1-month return →
Up and to the right = strong over both horizons. Integra LifeSciences is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×214150301101ATECIRMD300406EUZ6523688161300685300206300143IARTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Integra LifeSciences is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%214150301101IRMD300406CSTL3010216523688161300685300206IARTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Integra LifeSciences is the large dot.

Integra LifeSciences competitors and peer comparison

Head to head with its named competitors (IART vs SN..L vs ORGO vs MDT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Integra LifeSciences IART$1.08B-10%+1%12%6.0×5.9%
Smith & Nephew SN..L$12.6B+1%+2%17%14.2×11.1%
Organogenesis ORGOn/a-67%n/an/an/an/a
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Stryker SYK$121B-1%+8%25%19.9×10.7%

How Integra LifeSciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Integra LifeSciences against its 20 peers (data as of 18 Nov 2026)
MeasureIARTPeer medianRank in peer set
1-month return+4.0%-6.0%6th highest of 21
6-month return-9.9%-4.5%9th lowest of 20
Distance from 52-week high-32.4%-29.4%10th lowest of 21
Revenue growth (TTM)+0.8%+10.4%5th lowest of 19
Operating margin11.6%11.8%10th lowest of 20
Forward P/E6.0×18.5×cheapest of 12
Growth the price implies (Req g, 7 yrs)5.9%8.2%5th least demanding of 13
Growth delivered (Del g)+3.6%+10.1%4th lowest of 13
Hurdle (Req g minus delivered)+2.3 pp-2.6 pp5th most demanding of 13
ROIC minus cost of capital-2.1 pp+1.5 pp8th lowest of 19
EV / EBITDA8.0×10.3×2nd cheapest of 7
Net debt / EBITDA4.9×-0.3×2nd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a

Questions

Who are Integra LifeSciences's main competitors?
Named competitors: Smith & Nephew (SN..L), Organogenesis Holdings (ORGO), Medtronic (MDT), Stryker (SYK). The cockpit's measured peer set (industry) also includes CLASSYS (214150.KS), Freenome (FRNM), Mingyue Optical Lens (301101.SZ), Guangzhou Hexin Instrument (688622.SS), SI-BONE (SIBN), Alphatec (ATEC).
Is Integra LifeSciences expensive compared with its peers?
On forward p/e it trades at 6.0× against a peer median of 18.5×, cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Integra LifeSciences stock performed?
Over six months to 18 Nov 2026 the shares returned -9.9% against -4.5% for the median peer; over one year +18.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.